Ignite Creation Date:
2024-05-06 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05742945
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-19
First Post:
2023-02-15
Brief Title:
Can ILR Reduce the Risk of Arm Lymphedema
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Can Immediate Lymphatic Reconstruction With Lymphatico-Venous Anastomosis Reduce the Occurrence of Arm Lymphedema in Breast Cancer Patients After Axillary Lymph Node Dissection A Prospective Randomized Controlled Trial
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Breast cancer-related lymphedema BCRL is a debilitating usually lifelong burden for breast cancer survivors For the breast cancer patients receiving axillary lymph node dissection ALND the likelihood of BCRL is about 20 Lymphatico-venous anastomosis LVA has been accepted as a method of treating extremity lymphedema A few studies have mentioned the prophylactic effect of LVA on BCRL However there is still lack of a large-scale randomized controlled trial to corroborate its efficacy Therefore the goal of this study is to conduct a prospective randomized controlled trial to evaluate if immediate lymphatic reconstruction ILR with LVA could have a clinically significant effect on the reduction of BCRL occurrence
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None